- E-posternst.lien@uib.no
- BesøksadresseHaukeland universitetssykehus, Laboratoriebygget5009 Bergen
- PostadressePostboks 78045020 Bergen
Vitenskapelig artikkel
- (2020). First-in-human pharmacokinetics of tamoxifen and its metabolites in the milk of a lactating mother: A case study. ESMO Open. 1-5.
- (2019). Drug monitoring of tamoxifen metabolites predicts vaginal dryness and verifies a low discontinuation rate from the Norwegian Prescription Database. Breast Cancer Research and Treatment. 185-195.
- (2017). Serum concentrations of active tamoxifen metabolites predict long-term survival in adjuvantly treated breast cancer patients. Breast Cancer Research.
- (2016). A pooled analysis of CYP2D6 genotype in breast cancer prevention trials of low-dose tamoxifen. Breast Cancer Research and Treatment. 97-108.
- (2015). The active tamoxifen metabolite endoxifen (4OHNDtam) strongly down-regulates cytokeratin 6 (CK6) in MCF-7 breast cancer cells. PLOS ONE. 19 sider.
- (2015). Novel inflammatory biomarkers in primary hyperparathyroidism. European Journal of Endocrinology (EJE). 9-17.
- (2014). Illness uncertainty in breast cancer patients: Validation of the 5-item short form of the Mishel Uncertainty in Illness Scale. European Journal of Oncology Nursing. 1-7.
- (2014). Estradiol determines the effects of PTH on ERα-dependent transcription in MC3T3-E1 cells. Biochemical and Biophysical Research Communications - BBRC. 360-365.
- (2013). cAMP response element-binding protein interacts with and stimulates the proteasomal degradation of the nuclear receptor coactivator GRIP1. Endocrinology. 1513-1527.
- (2013). Serum concentrations of tamoxifen and its metabolites increase with age during steady-state treatment. Breast Cancer Research and Treatment. 243-248.
- (2013). A randomized phase II presurgical trial of weekly low-dose tamoxifen versus raloxifene versus placebo in premenopausal women with estrogen receptor-positive breast cancer. Breast Cancer Research. 11 sider.
- (2013). 1,25-dihydroxyvitamin D and the vitamin D receptor gene polymorphism apa1 influence bone mineral density in primary hyperparathyroidism. PLOS ONE. 8 sider.
- (2012). Vitamin B6 status and interferon-γ-mediated immune activation in primary hyperparathyroidism. Journal of Internal Medicine. 583-591.
- (2012). Tissue distribution of 4-hydroxy-N-desmethyltamoxifen and tamoxifen-N-oxide. Breast Cancer Research and Treatment. 693-700.
- (2012). Steroid receptor coactivators, HER-2 and HER-3 expression is stimulated by tamoxifen treatment in DMBA-induced breast cancer. BMC Cancer. 12 sider.
- (2011). Prognostic significance of Ki-67 labeling index after short-term presurgical tamoxifen in women with ER-positive breast cancer. Annals of Oncology. 582-587.
- (2011). Primary hyperparathyroidism influences the expression of inflammatory and metabolic genes in adipose tissue. PLOS ONE. 10 sider.
- (2011). Grapefruit juice and licorice increase cortisol availability in patients with Addison's disease. European Journal of Endocrinology (EJE). 761-769.
- (2010). Seasonal and age-related differences in serum 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D and parathyroid hormone in patients from Western Norway. Scandinavian Journal of Clinical and Laboratory Investigation. 281-286.
- (2010). Effect of low-dose tamoxifen on steroid receptor coactivator 3/amplified in breast cancer 1 in normal and malignant human breast tissue. Clinical Cancer Research. 2176-2186.
- (2010). Associations between tamoxifen, estrogens, and FSH serum levels during steady state tamoxifen treatment of postmenopausal women with breast cancer. BMC Cancer. 13 sider.
- (2009). Randomized double-blind 2 x 2 trial of low-dose tamoxifen and fenretinide for breast cancer prevention in high-risk premenopausal women. Journal of Clinical Oncology. 3749-3756.
- (2009). Randomized Biomarker Trial of Anastrozole or Low-Dose Tamoxifen or Their Combination in Subjects with Breast Intraepithelial Neoplasia. Clinical Cancer Research. 7053-7060.
- (2009). Nuclear receptor co-activators and HER-2/neu are upregulated in breast cancer patients during neo-adjuvant treatment with aromatase inhibitors. British Journal of Cancer. 1253-1260.
- (2009). Genotype-guided tamoxifen therapy: time to pause for reflection? The Lancet Oncology. 825-833.
- (2008). Tamoxifen impairs both longitudinal and cortical bone growth in young male rats. Journal of Bone and Mineral Research. 1267-1277.
- (2008). Recruitment of coactivator glucocorticoid receptor interacting protein 1 to an estrogen receptor transcription complex is regulated by the 3',5'-cyclic adenosine 5'-monophosphate-dependent protein kinase. Endocrinology. 4336-4345.
- (2008). Effects of CYP2D6 and SULT1A1 genotypes including SULT1A1 gene copy number on tamoxifen metabolism. Annals of Oncology. 56-61.
- (2007). A study of association between estrogen and tamoxifen metabolism, cytochrome 2D6 and sulfotransferae 1A1 polymorphisms, and sulfotransferase 1A1 gene copy number during steady sate tamoxifen treatment. Breast Cancer Research and Treatment. S144-S144.
- (2006). Pretreatment with tamoxifen does not change acute epirubicin cardiotoxicity in rats. Basic & Clinical Pharmacology & Toxicology. 231-234.
- (2006). Changes in bone and lipid metabolism in postmenopausal women with early breast cancer after terminating 2-year treatment with exemestane: A randomised, placebo-controlled study. European Journal of Cancer. 2968-75.
- (2005). Induction of hepatic drug-metabolising enzymes and tamoxifen metabolite profile in relation to administration route during low-dose treatment in nude rats. Journal of Steroid Biochemistry and Molecular Biology. 489-498.
- (2005). Identification and quantification of tamoxifen and four metabolites in serum by liquid chromatography-tandem mass spectrometry. Journal of Chromatography A. 6-14.
- (2005). Excretion of hydroxylated metabolites of tamoxifen in human bile and urine. Anticancer Research. 4487-4492.
- (2004). cAMP-dependent protein kinase regulates ubiquitin-proteasome-mediated degradation and subcellular localization of the nuclear receptor coactivator GRIP1. Journal of Biological Chemistry. 49120-49130.
- (2004). Tamoxifen and metabolite concentrations in serum and breast cancer tissue during three dose regimens in randomized preoperative trial. Clinical Cancer Research. 2336-2343.
- (2004). Phenotypic expression of the methylenetetrahydrofolate reductase 677C->T polymorphism and flavine cofactor availability in thyroid dysfunction. American Journal of Clinical Nutrition. 1050-1057.
- (2004). Betaine as a determinant of postmethionine load total plasma homocysteine before and after B-vitamin supplementation. Arteriosclerosis, Thrombosis and Vascular Biology. 301-307.
- (2003). Tamoxifen administration and metabolism in nude mice and nude rats. Journal of Steroid Biochemistry and Molecular Biology. 361-367.
- (2003). Homocysteine and its relations to B-vitamins and smoking in graves' disease before and after treatment. Journal of Internal Medicine. 504-512.
- (2003). Effect of tamoxifen at low doses on ultrasensitive C-reactive protein in healty women. Journal of Thrombosis and Haemostasis. 2149-2152.
- (2003). Determination of choline, betaine, and dimethylglycine in plasma by a high-troughput metod based on normal-phase chromatography-tandem mass spectrometry. Clinical Chemistry. 286-294.
- (2003). Characterization of receptor-interacting protein RIP140 in the regulation of SF-1 responsive target genes. Molecular and Cellular Endocrinology. 91-103.
- (2003). A randomized trial of low-dose tamoxifen on breast cancer proliferation and blood estrogenic biomarkers. Journal of the National Cancer Institute. 779-790.
- (2002). Tyreotoksisk periodisk paralyse - en uvanlig komplikasjon ved hypertyreose. Tidsskrift for Den norske legeforening. 1029-1031.
- (2002). Predictors of outcome and comparison of different drug regimens for the prevention of relapse in patients with Graves' disease. European Journal of Endocrinology (EJE). 583-589.
- (2001). Smoking, folate and methylenetetrahydrofolate reductase status as interactive determinants of adenomatous and hyperplastic polyps of colorectum. American Journal of Medical Genetics. 246-254.
- (2001). Plasma total homocysteine in hyper- and hypothyroid patients before and during 12 months of treatment. Clinical Chemistry. 1738-1741.
- (2001). Effect of low dose tamoxifen on the insulin-like growth factor system in healthy women. Breast Cancer Research and Treatment. 21-27.
- (2001). Correlation between tamoxifen elimination and biomarker recovery in a primary prevention trial. Cancer Epidemiology, Biomarkers and Prevention. 967-970.
- (2000). Selective oestrogen receptor modifiers (SERMs) and breast cancer therapy. Cancer Treatment Reviews. 205-227.
- (2000). Selective oestrogen receptor modifiers (SERMs) and breast cancer therapy. Cancer Treatment Reviews. 205-227.
- (2000). Plasma total homocysteine levels during short-term iatrogenic hypothyreoidism. Journal of Clinical Endocrinology and Metabolism (JCEM). 1049-1053.
- (1999). Serum homocysteine levels in postmenopausal breast cancer patients treated with tamoxifen. Cancer Letters. 73-77.
- (1999). Influence of aromatase inhibitors on plasma total homocysteine levels in postmenopausal breast cancer patients. Clinical Chemistry. 252-256.
- (1999). Influence of aromatase inhibitors on plasma total homocysteine in postmenopausal breast cancer patients. Clinical Chemistry. 252-256.
- (1999). Effect of blood tamoxifen concentrations on surrogate biomarkers in a trial of dose reduction. Journal of Clinical Oncology. 2633-2688.
- (1998). Thyroid function in postmenopausal breast cancer patients treated with tamoxifen. Scandinavian Journal of Clinical and Laboratory Investigation. 103-107.
- (1998). Thyroid function in postmenopausal breast cancer patients treated with tamoxifen. Scandinavian Journal of Clinical and Laboratory Investigation. 103-107.
- (1998). Thyroid function in postmenopausal breast cancer patients treated with tamoxifen. Scandinavian Journal of Clinical and Laboratory Investigation. 103-107.
- (1998). Plasma total homocysteine levels in hyperthyroid and hypothyroid patients. Metabolism: Clinical and Experimental. 89-93.
- (1998). Plasma total homocysteine levels in hyperthyroid and hypothyroid patients. Metabolism: Clinical and Experimental. 89-93.
- (1998). Plasma total homocysteine levels in hyperthyroid and hypothyroid patients. Metabolism: Clinical and Experimental. 89-93.
- (1998). Plasma total homocysteine levels in hyperthyroid and hypothyroid patients. Metabolism: Clinical and Experimental. 89-93.
- (1997). Treatment of small cell lung cancer (SCLC) with high dose tamoxifen in combination with epirubicin, cyclophosphamide and oncovin. European Journal of Clinical Pharmacology. 102.
- (1997). Effects of hormones on the plasma levels of the atherogenic amino acid homocysteine. Biochemical Society Transactions. 33-35.
- (1997). Effects of hormones on the plasma level of the atherogenic amino acid homocysteine. Biochemical Society Transactions. 33-35.
- (1995). Relations between sex hormones, sex hormone binding globulin, insulin-like growth factor-I and insulin-like growth factor binding protein-1 in post-menopausal breast cancer patients. Clinical Endocrinology. 23-30.
- (1995). Relations between sex hormones, sex hormone binding globulin insulin-like growth factor binding protein-1 in postmenopausal breast cancer patients. Clinical Endocrinology. 23-30.
- (1995). Plasma levels of the atherogenic amino acid homocysteine in post-menopausal women with breast cancer treated with tamoxifen. International Journal of Cancer. 365-368.
- (1995). Plasma levels of the atherogenic amino acid homocysteine in post-menopausal women with breast cancer treated with tamoxifen. International Journal of Cancer. 365-368.
- (1995). Pharmacokinetics of tamoxifen in pre- and post-menopausal women with breast cancer. Journal of Steroid Biochemistry and Molecular Biology. 229-231.
- (1995). Influence of tamoxifen on sex hormones, gonadotropins and sex hormone binding globulin in postmenopausal breast cancer patients. Journal of Steroid Biochemistry and Molecular Biology. 491-496.
- (1995). Influence of tamoxifen on sex hormones, gonadotrophins and sex hormone binding globulin in postmenopausal breast cancer patients. Journal of Steroid Biochemistry and Molecular Biology. 491-496.
- (1995). Determination of droloxifene and two metabolites in serum by high-pressure liquid chromatography. Therapeutic Drug Monitoring. 259-265.
- (1995). Determination of droloxifene and two metabolites in serum by high pressure liquid chromatography. Therapeutic Drug Monitoring. 259-265.
- (1994). Pharmacokinetics of anti-endocrine agents. Cancer Surveys. S. 343-370.
- (1994). High-dose (480 mg/day) tamoxifen with etoposide: a study of a potential multi-drug resistance modulator. Oncology. 79-83.
- (1992). Intermittent high dose tamoxifen as a potential modifier of multi-drug resistance. European Journal of Cancer. 805-810.
- (1992). Influence of tamoxifen, aminoglutethimide and goserelin on human plasma IGF-I levels in breast cancer patients. Journal of Steroid Biochemistry and Molecular Biology. 541-543.
- (1992). Influence of tamoxifen, aminoglutethimide and goserelin on human plasma IGF-1 levels in breast cancer patients. Journal of Steroid Biochemistry and Molecular Biology. 541-543.
- (1992). Influence of tamoxifen, aminoglutethimide and goserelin on human plasma IGF-1 levels in breast cancer patients. Journal of Steroid Biochemistry and Molecular Biology. 541-543.
- (1992). Influence of tamoxifen, aminoglutethimide and goserelin on human plasma IGF-1 levels in breast cancer patients. Journal of Steroid Biochemistry and Molecular Biology. 541-543.
- (1992). Influence of tamoxifen on plasma levels of insulinelike growth factor I and insulin-like growth factor binding protein I in breast cancer patients. Cancer Research. 4719-4723.
- (1992). Influence of tamoxifen on plasma levels of insulin-like growth factor I and insulin-like growth factor binding protein I in breast cancer patients. Cancer Research. 4719-4723.
- (1992). Influence of tamoxifen on plasma levels of IGF-I and IGFBP-I in breast cancer patients. Cancer Research. 4719-4723.
- (1992). Influence of tamoxifen on plasma levels of IGF-I and IGFBP-I in breast cancer patients. Cancer Research. 4719-4723.
- (1992). High dose tamoxifen as an enhancer of etoposide cytotoxicity.Clinical effects and in vitro assessment in p-glycoprotein expressing cell lines. British Journal of Cancer. 833-839.
- (1991). Distribution of tamoxifen and metabolites into brain tissue metastases in breast cancer patients. British Journal of Cancer. 641-645.
- (1991). Distribution of tamoxifen and metabolites into brain tissue and brain metastases in breast cancer patients. British Journal of Cancer. 641-645.
- (1991). Distribution of tamoxifen and its metabolites in tissues of rat and man during steady state treatment. Cancer Research. 4837-4844.
- (1991). Distribution of tamoxifen and its metabolites in rat and human tissues during steady state treatment. Cancer Research. 4837-4844.
- (1991). Distribution of Tamoxifen and meta-bolites into brain tissue and brain metastases in brain cancer patients. British Journal of Cancer. 641-645.
- (1990). Decreased serum concentrations of tamoxifen and its metabolites induced by aminogluethimide. Cancer Research. 5851-5857.
Vitenskapelig foredrag
- (2005). Distribution of tamoxifen in serum and breast cancer tissue and its effects on sex hormone-binding globulin (SHBG).
- (2004). Pharmacokinetics and pharmacodynamics of tamoxifen.
- (2002). Steroidogenesis - Role of Steroidogenic factor-1 and interacting nuclear receptor coregulators.
- (2001). Smoking, folate, and MTHFR C677T genotype as interactive determinants of adenomatous and hyperplastic polyps of colorectum.
- (2001). Homocysteine and thyroid function.
- (2000). Correlation between tamoxifen elimination and biomarker recovery in a promary prevention trial.
- (1999). Plasma levels of homocysteine are changed during treatment of hyper- and hypothyroidism.
- (1997). Phase 1 and pharmacokinetic study of high dose tamoxifen combined with epirubicin, cyclophosphamide and oncovin.
Leserinnlegg
- (2013). Breaking away: High fracture rates may merit a new trial of adjuvant endocrine therapy in Scandinavian breast cancer patients. Acta Oncologica. 861-U216.
- (2004). Letter. Journal of the National Cancer Institute. 883-883.
- (2001). Total plasma homocysteine in hypo- and hyperthyroidism: Covariations and causality. Journal of Clinical Endocrinology and Metabolism (JCEM). 1846.
Doktorgradsavhandling
- (2007). Nuclear Receptor Coregulators- Role of Protein-Protein Interactions and cAMP/PKA Signaling.
- (2007). Betaine and its relation to homocysteine status and one-carbon metabolism in humans : analytical method and biochemical studies.
- (2004). Pharmacology of low-dose tamoxifen regimens in breast cancer treatment.
- (2004). Graves' disease and hypothyroidism with emphasis on treatment, homocysteine and B-vitamins.
- (1991). Tamoxifen pharmacokinetics in breast cancer patients. Analytical methods, pharmacokinetics, tissue distribution and drug interactions. (dr.med.).
Dokumentar
- (2004). "En hormonell kriminalhistorie".
Vitenskapelig Kapittel/Artikkel/Konferanseartikkel
- (2012). Tamoxifen metabolism and biological activity. 22 sider.
- (2011). Steroid Receptor Coactivators and Their Expression, Regulation and Functional Role in Endocrine Responsive and Resistant Breast Cancer. 18 sider.
- (2011). Steroid Receptor Coactivators and Endocrine Treatment in Breast Cancer. 32 sider.
- (1999). Hormoner og hormonantagonister. 15 sider.
- (1998). Legemiddelanalyser og rusmiddelanalyser. 8 sider.
- (1994). Utprøving av dataprogrammet "Aldus Persuasion" og "Davis Transview Presenter" som hjelpemidler i forberedelse og gjennomføring av undervisning. 10 sider.
- (1991). Tamoxifen uptake in brain tissue and brain metastases in man.
Sammendrag/abstract
- (2013). Associations between tamoxifen and age during steady state tamoxifen treatment of postmenopausal women with breast cancer. Experimental and clinical endocrinology & diabetes. 1 sider.
- (2010). Grapefruit and Liquorice Increase Bioavailable Cortisol in Addison's Disease. Endocrine reviews. 1 sider.
- (2010). Effects of CYP2C19 genotype on tamoxifen and estrogen metabolism. European Journal of Cancer. 60-60.
- (2009). Ki-67 Expression after Tamoxifen Given Preoperatively Predicts Disease Free Survival and Overall Survival in Women with Operable ER-Positive Breast Cancer. Cancer Research. 517S-518S.
- (2008). Vitamin D-metabolism and PTH levels show a biphasic seasonal pattern but are not correlated to osteocalcin levels in outpatients from western Norway. Calcified Tissue International. S150-S151.
- (2008). A study of associations between estrogen and tamoxifen metabolism, cytochrome 2D6 and sulfotransferase 1A1 polymorphisms, and sulfotransferase 1A1 gene copy number during steady state tamoxifen treatment. Breast Cancer Research and Treatment. 592-592.
- (2007). Effect of CYP2D6 and SULT1A1 genotypes on the serum concentration of 4-hydroxytamoxifen and 4-hydroxy-N-demethyltamoxifen during steady state treatment of breast cancer patients. Breast. S15-S15.
- (2007). A study of associations between estrogen and tamoxifen metabolism, cytochrome 2D6 and sulfotransferase 1A1 polymorphisms, and sulfotransferase 1A1 gene copy number during steady state tamoxifen treatment. Breast Cancer Research and Treatment.
- (2005). Relationship between CYP2D6 and SULT1A1 genotypes and serum concentrations of tamoxifen and its metabolites during steady state treatment in breast cancer patients. Breast Cancer Research and Treatment. S236-S237.
Poster
- (2018). A prospective, longitudinal, breast cancer biobank (PBCB) in western Norway.
- (2013). Vitamin D levels in patients with primary hyperparathyroidism; a follow-up study after parathyroidectomy.
- (2012). Systemic Inflammation in Primary Hyperparathyroidism: Influences on Plasma Vitamin B6 Levels and Interferon-γ Mediated Immune Activation.
- (2011). Differential Expression of Inflammatory and Metabolic Genes in Adipose Tissue of Patients with Primary Huperparathyroidism.
- (2010). Expression of Steroid Receptor Coactivators and HER-2/neu in normal and malignant breast tissue in controls and tamoxifen treated patients.
- (2009). The Role of PKA and CREB in regulation of the Steroid Receptor Coactivator GRIP1/SRC-2.
- (2009). Relations between FSH, SHBG and tamoxifen metabolism during steady state tamoxifen treatment.
- (2009). PTH inhibits ligand-dependent activation of estrogen receptor alfa in MC3T3 osteoblasts.
- (2009). PTH inhibits ligand-dependent activation of estrogen receptor alfa in MC3T3 Osteoblasts.
- (2009). HER-2/neu and nuclear receptor coactivators are upregulated in breast cancer tumors during estrogen deprivation.
- (2008). Changes in mRNA expression levels of steroid receptor coactivators correlate with treatment response to aromatase inhibition in human breast cancer.
- (2007). Effect of CYP2D6 and SULT1A1 Genotypes on the serum concentration of 4-OHtamoxifen and 4-OH-N-Demethyltamoxifen during steady state treatment of breast cancer patients.
- (2007). A study of association between estrogen and tamoxifen metabolism, cytochrome 2D6 and sulfotransferae 1A1 polymorphisms, and sulfotransferase 1A1 gene copy number during steady sate tamoxifen treatment.
- (2006). ROLES OF cAMP RESPONSE ELEMENT BINDING PROTEIN (CREB) IN REGULATION OF GLUCOCORTICOID RECEPTOR INTERACTING PROTEIN 1 (GRIP1).
- (2005). Relationship between CYP2D6 and SULT1A1 genotypes and serum concentrations of tamoxifen and its metabolites during steady state treatment in breast cancer patients.
- (2005). Relationship between CYP2D6 and SULT1A1 genotype and serum concentration of tamoxifen and its metabolites during steady state treatment in breast cancer patients.
- (2005). Effects of low-dose tamoxifen treatment on expression of drug-metabolising enzymes in rat liver in relation to administration route.
- (2005). CHARACTERIZATION OF THE MOLECULAR MECHANISMS BY WHICH THE LEVEL OF NUCLEAR HORMONE RECEPTOR COACTIVATOR GRIP1 IS REGULATED.
- (2004). Tamoxifen metabolism and induction of hepatic drug-metabolizing enzymes in nude rats.
- (2004). Quantification of serum tamoxifen and metabolites by liquid chromatography-tandem mass spectrometry.
- (2002). Tamoxifen metabolism in immunocompromised rats and mice.
- (2001). Receptor Interacting Protein RIP140 inhibits transcriptional activity of Steroidogenic factor1.
- (2001). Receptor Interacting Protein RIP140 inhibits transcriptional activity of Steroidogenic factor-1.
- (2001). Receptor Interacting Protein RIP140 inhibits transcriptional activity of Steroidogenic factor-1.
- (2001). Plasma levels of homocysteine are changed during treatment of hyper- and hypo-thyroidism.
- (2001). A comparative study of tamoxifen metabolism in immunodeficient rats and nude mice.
- (2001). A comparative study of tamoxifen metabolism in immunodeficient nude rats and nude mice.
Fagartikkel
- (2022). Liquid biopsies and patient-reported outcome measures for integrative monitoring of patients with early-stage breast cancer: a study protocol for the longitudinal observational Prospective Breast Cancer Biobanking (PBCB) study. BMJ Open.